Compare Regeneron Pharmaceuticals Inc (REGN) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Rigetti Computing Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while Rigetti Computing Inc trades at $14.03 (market cap $4.72B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 16.1× Rigetti Computing Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Rigetti Computing Inc for 35 Days on average.
| REGN | RGTI | |
|---|---|---|
Market Cap | $76.14B | $4.72B |
Volume | 500,239 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $852.03 | $56.34 |
52-Week Low | $557.73 | $12.90 |
Typical Hold Time | 107 Days | 35 Days |
Enterprise Value | $70.85B | $4.33B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% on the day, with a bearish technical signal from moving averages. The company maintains strong fundamentals, including a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant immunology alliance expansion with Sanofi, valued up to $8 billion, which could drive future growth. Cash flow improved in 2025, with net cash flow turning positive at $634.70 million.
The outlook is positive, supported by robust profitability and strategic collaborations, but faces risks from competition in key drug markets and reliance on pipeline success. Analysts are bullish with a consensus price target of $849.84, implying potential upside. Investors should weigh strong financials against execution risks in drug development.
RGTI trades at $14.14, down 3.08% amid bearish technical signals despite recent quantum computing sector momentum. The company shows severe financial strain with a -1,787.4% net income margin and negative cash flow, though revenue grew from $7M to $13M year-over-year. Analyst sentiment remains strongly bullish with 85.7% buy ratings and a $21.67 consensus target, 53% above current price.
While Wall Street sees significant upside potential in RGTI's quantum computing technology, the stock faces substantial execution risks given persistent losses and cash burn. Investors must weigh the speculative growth narrative against fundamental weaknesses, with commercialization progress being the critical factor for valuation justification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
